ATLANTA, GA (Globe Newswire – October 7, 2025) — Holzer & Holzer, LLC is investigating whether Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) complied with federal securities laws. On August 7, 2025, Tandem announced “a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery.” Following this news, the price of the Company’s stock dropped.

If you purchased Tandem stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/tandem-diabetes-care/ to discuss your legal rights.